LORCAINIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H27ClN2O
Molecular Weight	370.916
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)N1CCC(CC1)N(C(=O)CC2=CC=CC=C2)C3=CC=C(Cl)C=C3

InChI

InChIKey=XHOJAWVAWFHGHL-UHFFFAOYSA-N

InChI=1S/C22H27ClN2O/c1-17(2)24-14-12-21(13-15-24)25(20-10-8-19(23)9-11-20)22(26)16-18-6-4-3-5-7-18/h3-11,17,21H,12-16H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C22H27ClN2O
Molecular Weight	370.916
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://pmmp.cnki.net/Resources/CDDPdf/med%5Cbase%5C%E9%BA%BB%E9%86%89%E8%8D%AF%E5%8F%8A%E5%85%B6%E8%BE%85%E5%8A%A9%E8%8D%AF%E7%89%A9%5C2915.pdf | https://www.scientificamerican.com/article/trial-sans-error-how-pharma-funded-research-cherry-picks-positive-results/

Lorcainide is a class Ic antiarrhythmic medication. It was reported to be highly efficient for the treatment of ventricular arrhythmias, ventricular fibrillation, and tachycardia. The drug was used under the name Remivox. The mechanism of lorcainide action involves the blockage of sodium channels. Lorcainide was withdrawn from the market for a commercial reason, but later it was admitted that the use of the drug is associated with high risk of death.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium channel alpha subunit 76 Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8358576	Blocker 537

Conditions

Condition	Modality	Highest Phase	Product
Ventricular arrhythmia 50 Sources: http://pmmp.cnki.net/Resources/CDDPdf/med%5Cbase%5C%E9%BA%BB%E9%86%89%E8%8D%AF%E5%8F%8A%E5%85%B6%E8%BE%85%E5%8A%A9%E8%8D%AF%E7%89%A9%5C2915.pdf	Primary	Withdrawn	Unknown Approved Use For the stability of ventricular arrhythmias, ventricular tachycardia, ventricular fibrillation, ventricular contraction, supraventricular tachycardia and intractable ventricular tachycardia.
Ventricular tachycardia 11 Sources: http://pmmp.cnki.net/Resources/CDDPdf/med%5Cbase%5C%E9%BA%BB%E9%86%89%E8%8D%AF%E5%8F%8A%E5%85%B6%E8%BE%85%E5%8A%A9%E8%8D%AF%E7%89%A9%5C2915.pdf	Primary	Withdrawn	Unknown Approved Use For the stability of ventricular arrhythmias, ventricular tachycardia, ventricular fibrillation, ventricular contraction, supraventricular tachycardia and intractable ventricular tachycardia.
Supraventricular tachycardia 8 Sources: http://pmmp.cnki.net/Resources/CDDPdf/med%5Cbase%5C%E9%BA%BB%E9%86%89%E8%8D%AF%E5%8F%8A%E5%85%B6%E8%BE%85%E5%8A%A9%E8%8D%AF%E7%89%A9%5C2915.pdf	Primary	Withdrawn	Unknown Approved Use For the stability of ventricular arrhythmias, ventricular tachycardia, ventricular fibrillation, ventricular contraction, supraventricular tachycardia and intractable ventricular tachycardia.
Ventricular fibrillation 4 Sources: http://pmmp.cnki.net/Resources/CDDPdf/med%5Cbase%5C%E9%BA%BB%E9%86%89%E8%8D%AF%E5%8F%8A%E5%85%B6%E8%BE%85%E5%8A%A9%E8%8D%AF%E7%89%A9%5C2915.pdf	Primary	Withdrawn	Unknown Approved Use For the stability of ventricular arrhythmias, ventricular tachycardia, ventricular fibrillation, ventricular contraction, supraventricular tachycardia and intractable ventricular tachycardia.

PubMed

Title	Date	PubMed
[Effects of lorcainide, a new antiarrhythmic agent, on experimental cardiac arrhythmias].	1983 Feb	6852683
Congestive heart failure induced by six of the newer antiarrhythmic drugs.	1989 Nov 1	2509529
Frequency dependent prolongation of effective refractory period by a complex class III antiarrhythmic agent CPU-86017.	2001 Jan	11730558
The contribution of refractoriness to arrhythmic substrate in hypokalemic Langendorff-perfused murine hearts.	2007 May	17295037
Outcome based subgroup analysis: a neglected concern.	2009 May 20	19454041
Reporting bias in medical research - a narrative review.	2010 Apr 13	20388211

Sample Use Guides

In Vivo Use Guide

Lorcainide is given orally at a dose 50-100 mg 2-3 times/day after a meal; the drug can be also administered as a slow intravenous injection at a dose of 1-2 mg for 5-10 min and the dose can be repeated every 8-12 h.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:53:33 GMT 2023` Edited by `admin` on `Sat Dec 16 17:53:33 GMT 2023`
Record UNII	KGJ2T0N7IQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LORCAINIDE

Official Name

English

BENZENEACETAMIDE, N-(4-CHLOROPHENYL)-N-(1-(1-METHYLETHYL)-4-PIPERIDINYL)-

Systematic Name

English

LORCAINIDE [MI]

Common Name

English

N-(4-CHLOROPHENYL)-N-(1-(1-METHYLETHYL)-4-PIPERIDINYL)BENZENEACETAMIDE

Systematic Name

English

lorcainide [INN]

Common Name

English

RO-13-1042

Code

English

4'-CHLORO-N-(1-ISOPROPYL-4-PIPERIDYL)-2-PHENYLACETANILIDE

Systematic Name

English

Lorcainide [WHO-DD]

Common Name

English

RO 13-1042

Code

English

Classification Tree Code System Code

WHO-VATC

QC01BC07